Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/31/11
End: 09/30/14
Due: 09/30/15
Phase: N/A
Priority: Normal
Start: 03/31/12
End: 03/31/16
Due: 03/31/17
Phase: N/A
Priority: Normal
Start: 04/30/09
End: 09/30/15
Due: 09/30/16
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer | NCT01388647 | Vector Oncology | user2@example.com | None | 2011-08-31 | 2014-09-30 | 2015-09-30 | - | - | 2025-07-14 |
| Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | NCT01506596 | Vector Oncology | user2@example.com | None | 2012-03-31 | 2016-03-31 | 2017-03-31 | - | - | 2025-07-14 |
| Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors | NCT00800345 | Vector Oncology | user2@example.com | None | 2009-04-30 | 2015-09-30 | 2016-09-30 | - | - | 2025-07-14 |